Laddar populära aktier...
ODI Pharma announced on June 25th that the company has completed a first delivery of products to the...
Redeye provides its view on the recent financing of SEK80m and the 18-month OPTIMIZE-1 readout, a ph...
Investors House announced today that it has divested its 1/3 stake in Jyväskylän Kukkulan Kehitys Oy...
We forecast 21% y-o-y ARR growth and 15% adj. EBITDA margin.
CoinShares International (CS) är en pionjär och en väletablerad aktör i den framväxande och snabbväx...
Summarising an eventful H1'24 Many players in the Parkinson's therapy game.
We make minor changes to adjusted EBITA for 2024E-26E ahead of Q2.
Verve (formerly MGI – Media and Games Invest) has announced the acquisition of Jun Group for €170m (...
The European Medicines Agency (EMA) has approved Cereno Scientific’s Clinical Trial Application (CTA...
Clavister could provide cybersecurity to Thales' SOTAS communication system A tangible revenue case ...
Redeye retains its positive view of Fortnox. While management should have clarified it was talking a...
Biovica records IVD test sales in Q4, which are higher than Q1-Q3, and research test sales have incr...
Redeye comments on the news that the company’s complementary clinical study TRIAC II, which focused ...
Redeye provides a comment on the outcome in Scandinavian ChemoTech’s rights issue.
Redeye comments on Verve’s acquisition of Jun Group, which strengthens its position on the demand si...